Paper · 36917948

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.

de Visser KE and 1 other. Cancer Cell, 2023. Cited by 3,317 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Papers, record 36917948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36917948

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.; PubMed
Journal: Cancer Cell; PubMed
Year: 2023; PubMed
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/36917948/; PubMed
DOI: https://doi.org/10.1016/j.ccell.2023.02.016; PubMed
The journal: https://conductscience.org/library/journal-index/101130617; PubMed
Citations, by iCite: 3,317; iCite
Relative citation ratio, by iCite: 352; iCite
Revised in PubMed: 2023-03-21; PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	de Visser KE	Karin E
2	Joyce JA	Johanna A

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Endothelial Cells	Major topic
Neoplasms	Major topic
Humans
Ecosystem
Carcinogenesis
Cell Transformation, Neoplastic
Tumor Microenvironment

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
	Cancer Research UK	United Kingdom		PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by2,535

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,317 citations.

PMID	Title	Journal	Year	In Papers	Source
42,984,998	Intratumoral habitat combined with peritumoral radiomics to improve the predictive performance of initial TACE efficacy: a multicenter retrospective study.	Front Oncol	2026	https://conductscience.org/library/papers/42984998	PubMed
42,984,982	Microbiome-mitochondria crosstalk in neuro-oncology: molecular mechanisms, immunometabolic reprogramming, and therapeutic opportunities.	Front Microbiomes	2026	https://conductscience.org/library/papers/42984982	PubMed
42,980,855	Synthesizing multi-omics evidence of interface-specific selection in lung adenocarcinoma metastasis: A trait-origin-interface-function framework across lymph-node and brain ecosystems.	Funct Integr Genomics	2026	https://conductscience.org/library/papers/42980855	PubMed
42,978,882	Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications.	Front Immunol	2026	https://conductscience.org/library/papers/42978882	PubMed
42,977,983	Ubiquitination in cancer: mechanisms, signaling networks and potential therapeutic opportunities.	Mol Cancer	2026	https://conductscience.org/library/papers/42977983	PubMed
42,975,718	Taurine bolsters adoptive T cell therapy efficacy against hepatocellular carcinoma by reprogramming T cell function.	Cancer Immunol Immunother	2026	https://conductscience.org/library/papers/42975718	PubMed
42,974,916	Impacts of mutation accumulation and order on tumor initiation revealed by engineered murine colorectal cancer organoids.	Elife	2026	https://conductscience.org/library/papers/42974916	PubMed
42,972,983	An Immune-Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer.	Cancer Med	2026	https://conductscience.org/library/papers/42972983	PubMed
42,972,485	The TGF-β signaling activated by cancer-associated macrophages promotes cancer stemness and Gefitinib resistance in EGFR-mutant non-small-cell lung cancer.	Stem Cell Res Ther	2026	https://conductscience.org/library/papers/42972485	PubMed
42,972,293	Multi-omics characterization of CAF-related transcriptional programs reveals a smoking-context-informed 11-gene prognostic signature in HNSCC.	BMC Cancer	2026	https://conductscience.org/library/papers/42972293	PubMed

1 to 10 of 2,535

See all 2,535 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36917948

GET https://conductscience.org/api/papers/v1/36917948/cited_by?page=2

API reference For AI assistants